

- Iful

1617

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gosse B. Bruinsma

Serial No.: 10/593,179

Filed: October 4, 2006 (presumed)

For: METHOD OF TREATING DOWN

SYNDROME

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3154-6272.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandrai, VA 22313-1450.

October 10, 2006

Date

Betty Vowles

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Foreign Patent Documents

Document No.

Publication Date

Patentee

WO 03/082270 A1

10-09-2003

Axonyx, Inc.

Serial No.: 10/593,179

Other Documents

Cure Research for Alzheimer's Disease, (visited 1/7/2004) http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm.

PRASHER et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--Pilot Study, International Journal of Geriatric Psychiatry, 2002, pp. 270-78, Vol. 17.

SHAW et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, PNAS, June 19, 2001, pp. 7605-10, Vol. 98, No. 13.

PATEL et al., Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor, Jan. 1998, pp. 171-76, Vol. 9, No. 1.

This Supplemental Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041

Attorney for Applicant

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: October 10, 2006

ACT/bv

Enclosures: Form PTO/SB/08

Cited Non-U.S. Patent Documents

Document in ProLaw

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of

ubstitute for form 1449A/PTO

Sheet

	Complete if Known
Application Number	10/593,179
Filing Date	October 4, 2006 (presumed)
First Named Inventor	Gosse B. Bruinsma
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	3154-6272.1US

Publication Date Passages or Relevant Pa	arriver Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Releva
US-		Number - Kind Code ² (if known)		Cited Document	Passages or Relevant
US-	-				
US-					
US-		300			
US-		The state of the s			
US-		- Par			
US-			The state of the s		
US-			-	 	
US-			The state of the s		
US- US- US- US- US-					
US- US- US- US-		US-			
US- US- US-		US-			
US- US-		US-			
US-		US-			
					No. of the last of
US-					The same of the sa
US-					The state of the s
		US-			The state of the s

FOREIGN PATENT DOCUMENTS									
Examiner Cite		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,				
lnitials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶			
/R.H./		WO 03/082270 A1	10-09-2003	Axonyx, Inc.					
	· · · ·		+ +						
	-		+						
					1				

		Examiner Signature	/Raymond Henley Iii/	Date Considered	07/10/2009	
--	--	-----------------------	----------------------	--------------------	------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known		
INITIO	DIFORMATION DIGGLOCUPE		Application Number	10/593,179		
INFORMATION DISCLOSURE		Filing Date	October 4, 2006 (presumed)			
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Gosse B. Bruinsma	
				Group Art Unit	To be assigned	
(use as many sheets as necessary)		Examiner Name	To be assigned			
Sheet	2	of	2	Attorney Docket Number	3154-6272.1US	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.H./		Cure Research for Alzheimer's Disease, (visited 1/7/2004) http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm .	
/R.H./		PRASHER et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheinier's diseasePilot Study, International Journal of Geriatric Psychiatry, 2002, pp. 270-78, Vol. 17.	
R.H./		SHAW et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, PNAS, June 19, 2001, pp. 7605-10, Vol. 98, No. 13.	
/R.H./		PATEL et al., Abstract, Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor, Jan. 1998, pp. 171-76, Vol. 9, No. 1.	

Examiner	/Raymond Henley lii/	Date	07/10/2009	
Signature	/naymond hemey m/	Considered	01/10/2003	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.